Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001104659-25-015743
Filing Date
2025-02-20
Accepted
2025-02-20 17:33:25
Documents
1
Period of Report
2025-02-20

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm257186-4_4seq1.html 4  
1 OWNERSHIP DOCUMENT tm257186-4_4seq1.xml 4 7296
  Complete submission text file 0001104659-25-015743.txt   8953
Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX 44 1235 430000
Adaptimmune Therapeutics PLC (Issuer) CIK: 0001621227 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O ADAPTIMMUNE THERAPEUTICS PLC 60 JUBILEE AVE, MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX
Business Address
Lunger John (Reporting) CIK: 0001784487 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37368 | Film No.: 25647506